April 12, 2021—DiaSorin has signed a definitive merger agreement to acquire Luminex for a total equity value of about $1.8 billion.
Luminex, headquartered in Austin, Tex., develops, manufactures, and sells proprietary biological testing technologies and products throughout the diagnostics and life science industries. Through the acquisition, DiaSorin, based in Italy, will gain access to Luminex’s molecular diagnostics multiplexing technology and portfolio, including a menu of solutions in infectious diseases, respiratory infections, vector-borne diseases, hospital-acquired infections, gastroenterology infections, genetics, and women’s health, expanding DiaSorin’s presence in the United States. The acquisition will also provide DiaSorin access to Luminex’s applications in the life science industry while accelerating the availability of Luminex’s technology and solutions outside the U.S. through DiaSorin’s extensive commercial and geographical reach.
“We are really excited about this transaction, which we believe creates value for our shareholders and represents an outstanding opportunity for our future growth, positioning DiaSorin and Luminex as a unique combination of diagnostic specialists,” Carlo Rosa, CEO of DiaSorin Group, said in a press statement. “Luminex perfectly fits with our strategy to grow our positioning in the molecular diagnostics space, to broaden our presence in the U.S., and to create additional value through life science offerings.”
The transaction is expected to close within the third quarter of this year.